| Loss of CHD1 promotes heterogeneous mechanisms of resistance to AR-targeted therapy via chromatin dysregulation Z Zhang, C Zhou, X Li, SD Barnes, S Deng, E Hoover, CC Chen, YS Lee, ... Cancer cell 37 (4), 584-598. e11, 2020 | 117 | 2020 |
| YAP drives fate conversion and chemoresistance of small cell lung cancer Q Wu, J Guo, Y Liu, Q Zheng, X Li, C Wu, D Fang, X Chen, L Ma, P Xu, ... Science Advances 7 (40), eabg1850, 2021 | 71 | 2021 |
| Loss of VGLL 4 suppresses tumor PD‐L1 expression and immune evasion A Wu, Q Wu, Y Deng, Y Liu, J Lu, L Liu, X Li, C Liao, B Zhao, H Song The EMBO journal 38 (1), e99506, 2019 | 54 | 2019 |
| Ectopic JAK–STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance S Deng, C Wang, Y Wang, Y Xu, X Li, NA Johnson, A Mukherji, UG Lo, ... Nature cancer 3 (9), 1071-1087, 2022 | 53 | 2022 |
| MEKK2 and MEKK3 suppress Hedgehog pathway-dependent medulloblastoma by inhibiting GLI1 function J Lu, L Liu, M Zheng, X Li, A Wu, Q Wu, C Liao, J Zou, H Song Oncogene 37 (28), 3864-3878, 2018 | 38 | 2018 |
| Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer X Li, Y Wang, S Deng, G Zhu, C Wang, NA Johnson, Z Zhang, CR Tirado, ... Cancer cell 41 (8), 1427-1449. e12, 2023 | 17 | 2023 |
| Hepatic loss of Lissencephaly 1 (Lis1) induces fatty liver and accelerates liver tumorigenesis in mice X Li, L Liu, R Li, A Wu, J Lu, Q Wu, J Jia, M Zhao, H Song Journal of Biological Chemistry 293 (14), 5160-5171, 2018 | 17 | 2018 |
| Selective ablation of tumor suppressors in parafollicular C cells elicits medullary thyroid carcinoma H Song, C Lin, E Yao, K Zhang, X Li, Q Wu, PT Chuang Journal of Biological Chemistry 292 (9), 3888-3899, 2017 | 16 | 2017 |
| UBE2J1 is the E2 ubiquitin-conjugating enzyme regulating androgen receptor degradation and antiandrogen resistance C Rodriguez Tirado, C Wang, X Li, S Deng, J Gonzalez, NA Johnson, ... Oncogene 43 (4), 265-280, 2024 | 7 | 2024 |
| The LIS1/NDE1 complex is essential for FGF signaling by regulating FGF receptor intracellular trafficking L Liu, J Lu, X Li, A Wu, Q Wu, M Zhao, N Tang, H Song Cell reports 22 (12), 3277-3291, 2018 | 7 | 2018 |
| The critical interplay of CAF plasticity and resistance in prostate cancer X Li, P Mu Cancer research 83 (18), 2990-2992, 2023 | 5 | 2023 |
| Author Correction: Ectopic JAK–STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance S Deng, C Wang, Y Wang, Y Xu, X Li, NA Johnson, A Mukherji, UG Lo, ... Nature Cancer 3 (10), 1271, 2022 | 2 | 2022 |
| ZNF397 Deficiency Triggers TET2-driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer Y Xu, Y Yang, Z Wang, M Sjöström, Y Jiang, Y Tang, S Cheng, S Deng, ... Cancer Discovery, OF1-OF26, 2024 | 1 | 2024 |
| JAK-STAT Signaling Enables Lineage Plasticity-driven AR Targeted Therapy Resistance S Deng, C Wang, Y Wang, Y Xu, X Li, NA Johnson, UG Lo, L Xu, ... bioRxiv, 2021.11. 02.466956, 2021 | 1 | 2021 |
| Abstract PO-117: CHD1-loss promotes tumor heterogeneity and therapy resistance in prostate cancer Z Zhang, C Zhou, X Li, C Sawyers, P Mu Cancer Research 80 (21_Supplement), PO-117-PO-117, 2020 | 1 | 2020 |
| The interplay of SYNCRIP deficiency, APOBEC activity, and extrachromosomal DNA in castration-resistant prostate cancer drug resistance X Li, S Deng, C Wang, Y Wang, P Mu Cancer Research 84 (6_Supplement), 4311-4311, 2024 | | 2024 |
| Restoring our ubiquitination machinery to overcome resistance in cancer therapy X Li, P Mu Oncoscience 11, 43, 2024 | | 2024 |
| Abstract PR001: An endogenous molecular brake preventing APOBEC-driven tumor mutational burden, heterogeneity and AR therapy resistance P Mu, X Li, Y Wang Cancer Research 83 (11_Supplement), PR001-PR001, 2023 | | 2023 |
| Epigenetic rewiring promotes antiandrogen resistance and metastasis via heterogenous oncogenic drivers in prostate cancer X li, S Deng, J Gonzalez, CR Tirado, C Wang, NA Johnson, L Metang, ... Cancer Research 83 (7_Supplement), 3891-3891, 2023 | | 2023 |
| An endogenous molecular brake preventing APOBEC-driven tumor mutational burden, heterogeneity and therapy resistance P Mu, X Li, Y Wang, T Wang, S Deng Cancer Research 83 (7_Supplement), 93-93, 2023 | | 2023 |
Jinqiu LuPostdoctoral Research Scientist, Columbia University Medical Center在 cumc.columbia.edu 的电子邮件经过验证
